Research programme: antibody-drug conjugates - Medarex
Alternative Names: MDX-1206Latest Information Update: 16 Jul 2016
At a glance
- Originator Medarex
- Class Monoclonal antibodies
- Mechanism of Action Alkylating agents; Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported B-cell lymphoma; Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in B-cell lymphoma in USA (Parenteral)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
- 01 Apr 2010 Preclinical trials in B-cell lymphoma in USA (Parenteral)